All In Biotech

Drug Trial Radar · NCT00352703

PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation

An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation

Last checked: Nov 20, 2026Latest source record: Nov 3, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

145

Actual

Start

Apr 2006

Primary completion

Apr 2007

Study completion May 2007

Sponsor

Lead sponsor
Swedish Orphan BiovitrumIndustry
Sponsor type
Industry
First posted
Jul 17, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, single-arm, multicentre study conducted in Spain to estimate the effectiveness of palifermin administered at a dose of 60 mg/kg/day IV for 3 consecutive days before the start of the conditioning regimen and for 3 consecutive days after autologous PBSCT for treating oral mucositis in patients with NHL and MM who have received high-dose conditioning chemotherapy.

Conditions

  • Non-Hodgkin's Lymphoma
  • Multiple Myeloma

Interventions

  • Kepivance (Palifermin)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary efficacy endpoints are the incidence (%) and duration of severe oral mucositis (WHO grades 3 or 4).Time frame: Up to 40 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.